Tandem Diabetes Care Q3 2026 Earnings - TANDEM DIABETES CARE INC

Explicit Guidance:

• FY2026 Revenue: Worldwide sales expected in the range of $1.65 billion to $1.685 billion (typo in transcript "1,085" corrected to $1.685 based on segment ranges).
  • U.S. Sales: $730 million to $745 million.
  • International Sales: $335 million to $340 million.
• FY2026 Margins: Gross margin expected at 56% to 57%; Adjusted EBITDA margin expected at 5% to 6% of annual sales.
• FY2027 Outlook: No specific numerical guidance provided yet. Management indicates revenue growth is likely in the mid-to-high single digits, suggesting a recalibration from consensus estimates of ~12% due to the pharmacy channel transition dynamics.
• Pharmacy Metrics: Fourth quarter 2026 pump shipments expected to be 15–20% via pharmacy; FY2026 average expected to be 10–12% of total pumps (revised down from initial 20% target).
• Supply ASP: Net supply Average Selling Prices (ASP) in pharmacy channel currently averaging closer to $400/month (vs. baseline of $350), though management advises tempering expectations as data is limited to two quarters.

Business-Segment Outlook:

• U.S. Pharmacy Channel: Transition to pay-go reimbursement model anticipated to reach full scale (nearly 100% pharmacy vs. DME) by the end of 2028. Current formulary coverage at 50% of covered lives; expected to expand further by the time of full Mobi Tubeless launch.
• U.S. Market Dynamics: New pump starts returned to growth in Q3; MDI conversions represent 70% of new customers, with MDI growth of nearly 10% in Q3. Mobile device (Mobi) drives conversion from insulin pen users.
• International Markets: Direct commercial operations expanded to UK, Switzerland, Austria, and France (Q4 2026). Goal to serve 30% of international installed base directly by end of 2026, scaling to 50% by end of 2027. International revenue grew 26% YoY in Q3; direct channel revenue represented 18% of international revenue in Q3, with a 30% sequential shipment increase in direct markets.
• Product Portfolio:
  • Mobi Tubeless: Awaiting FDA clearance (late-stage review). Anticipated commercial launch in first half of 2027. Initially submitted for abdominal wear, with plans to add arm wear and other insulin types via FDA mechanisms post-clearance.
  • AutoSoft Plus: Global launch initiated in Q3; expansion to additional geographies expected in early 2027, pending regulatory approval.
  • SteadySet: Planned for launch following Mobi Tubeless clearance (2027).

Market and Competitive Outlook:

• Market Penetration: Current pump penetration estimated in the high 30s to 40%; long-term target potential of 65%+.
• Competitive Positioning: Tubeless and automated insulin delivery (AID) viewed as the "fastest-growing segment" of the pump market. Mobi Tubeless positioned to compete directly with existing tubeless options.
• Adoption Drivers: Fully closed-loop systems expected to drive adoption by removing meal announcements, targeting Type 1 and Type 2 patients seeking "set and forget" simplicity.

Macro / Industry Outlook:

• C-Peptide Regulation: Anticipates resolution of the C-peptide testing requirement for Type 2 diabetes reimbursement from CMS; expects a decision "soon," noting the election may have caused a delay from the August timeframe.
• Supply Chain: Infusion set supply shortages improving in Q3 but expected to persist into early 2027, prompting the AutoSoft Plus and SteadySet launches.
• Currency: International growth mentioned in constant currency terms (27% up YoY in Q3), indicating management monitors FX impacts on international performance.

Strategic Initiatives:

• Leadership Transition: John Sheridan (CEO since 2013) retiring at end of 2026; Jeanette Bankas officially joins as President and CEO on November 16, 2026.
• Fully Closed Loop (FCL): Pivotal study for UVA's 8-in-1 algorithm (Type 1, Type 2, adolescents) expected to begin in Q4 2026 with ~300–400 patients. Data collection duration estimated at 3–4 quarters; FDA submission targeted for end of 2027, with product market launch expected in 2028.
• International Expansion: Continued expansion of direct operations across Europe in 2027 to capture greater economic value and improve customer relationships.
• Business Model: Shift from DME (Direct Market Entry) to Pharmacy distribution; initial revenue headwinds from $0 pump upfront cost offset by higher recurring supply revenue.

Risks and Headwinds to Outlook:

• Pharmacy Transition Headwinds: "Gradual" adoption of pharmacy pump shipments compared to supply conversions is creating sales headwinds extending into 2027. If pharmacy pump adoption outpaces supply base conversion, revenue growth may be dampened.
• Regulatory Timelines: Delays in FDA clearance for Mobi Tubeless or the FCL pivotal study could impact launch timing and commercial availability in 2027–2028.
• Supply Constraints: Continued shortages of third-party infusion sets impacting early 2027 operations.
• Revenue Recalibration: Management notes that outperformance in pharmacy pump volume could have a negative impact on total sales revenue due to the shift in ASP mix (lower upfront pump revenue vs. higher recurring supply).
• Operational Transition: CEO transition timing and execution risks during the final months of 2026.

Management Tone on the Future:

• Confidence: Management expressed "high confidence" in the business's ability to deliver on strategic priorities despite the slower-than-anticipated pharmacy ramp.
• Reassurance: Reiterated that the business fundamentals are "strong" and the transition to a sustainable, profitable growth model is on track.
• Forward-Looking Sentiment: Described the FCL and Mobi Tubeless as "game changers" and noted the international market as "underappreciated" with "really exciting stuff" expected.
• Caveat: Acknowledged a need to "re-calibrate" external models for 2027 and advised patience regarding the pharmacy conversion timeline.

Miscellaneous:

• Timeline Adjustments: The initial assumption of 20% pharmacy pump shipments in Q4 was revised to 15–20% (average 10–12% for the year).
• Cost Structure: SG&A increased due to commercial investments worldwide, offset by a $5 million decline in stock-based compensation; R&D remained flat.